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In their commentary, Drs. Takahashi and Nishibori 1
discuss putative antitumour effects of statins. How-
ever, prospective data suggest that statins actually in-
crease cancer in certain segments of the population.
Additionally, new findings regarding the immuno-
modulatory effects of statins may explain the mecha-
nism by which that increase occurs 2.
Statins increase the number of regulatory T cells
(Tregs) in vivo by inducing the transcription factor
forkhead box P3 2. Although that increase may be ben-
eficial in stabilizing atherosclerotic plaque by reducing
the effector T-cell response within the atheroma 3, it
might impair both the innate 4 and adaptive 5 host anti-
tumour immune responses. Not surprisingly, the number
of Tregs present in many solid tumours correlate in-
versely with patient survival 6.
Indeed, analysis of large randomized statin trials
demonstrate a highly significant (p = 0.009) inverse as-
sociation between achieved low-density lipoprotein cho-
lesterol levels and cancer 7. Close inspection of statin
trials reveal the specific populations at risk for the de-
velopment of incident cancer with statin treatment. These
include the elderly 8–10 and people with a history of breast
or prostate cancer 11,12. Furthermore, statin-treated in-
dividuals undergoing immunotherapy for cancer may be
at increased risk for worsening cancer 13.
The elderly are relatively immunosuppressed and
are more likely to harbour occult cancers 14. In the
PROSPER (Prospective Study of Pravastatin in the Eld-
erly at Risk) trial 8, a 3.2-year prospective study of
pravastatin for cardiovascular disease prevention in the
elderly (mean age at trial entry: 75 years) at high risk
for cardiovascular disease, cancer incidence was sig-
nificantly increased in subjects randomized to pra-
vastatin. In fact, the increase in cancer mortality
equalled in magnitude the decrease in cardiovascular
disease mortality in the statin-treated patients, leaving
all-cause mortality unchanged. Likewise, post hoc
analysis of the LIPID study 9, a 6-year prospective trial
of pravastatin in individuals with cardiovascular dis-
ease, revealed a significant increase in cancer inci-
dence in the elderly subjects (age: 65–75 years) ran-
domized to pravastatin. In a secondary analysis of the
TNT (Treating to New Targets) study 10, elderly sub-
jects randomized to high-dose atorvastatin (80 mg daily)
versus low-dose atorvastatin (10 mg daily) demon-
strated a trend toward increased death, largely from
an increase in cancer mortality. Therefore, the increase
in incident cancer in the elderly might be dose-related.
It is highly plausible that the elderly are particularly
sensitive to a statin-induced increase in Tregs, further
impairing their immune response to cancer.
An alarming increase in breast cancer incidence,
some of which were recurrences, was seen in women
randomized to pravastatin in the CARE trial 11. Thereaf-
ter, cancer was an exclusion criterion in randomized
statin trials. In clinical practice, however, it is not infre-
quent to find an association between recurrence of breast
cancer and concurrent statin therapy 15. Long-term
follow-up (10 years after trial completion) of WOSCOPS
(West of Scotland Coronary Prevention Study), a 5-year
prospective trial of pravastatin in hypercholesterolemic
men, revealed an increase in prostate cancer in the men
who were randomized to pravastatin therapy 12. That
finding indicates that cancers may become evident a
decade or more after treatment with statins. Treg in-
creases have been associated with both breast and pros-
tate cancers 16,17, and therefore, it is highly plausible
that the increase in cancers seen with statin therapy is
related to a statin-induced increase in Tregs.
Statin therapy has been associated with tumour pro-
gression leading to radical cystectomy in patients treated
for bladder cancer with bacille Calmette–Guérin im-
munotherapy 13. That association may be likewise due
to a statin-induced increase in Tregs, resulting in im-
paired host antitumour immunity.
Statin trials have typically randomized subjects free
of prevalent cancers and have been about 5 years in
duration. Long-term follow-up data are limited, particu-
larly for the development of cancer. Statins are nowGOLDSTEIN et al.
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promoted for widespread use in adults of all ages and
at high doses 18, potentially for decades. Importantly,
they are used in individuals with other significant
comorbidities such as cancer. Unfortunately, the post-
market surveillance of drugs has been poor 19. Because
cancer is highly prevalent in the population, particu-
larly in the elderly, a statin-induced increase in cancer
incidence will likely go unrecognized.
Long-term prospective data are needed on the fea-
sibility of statin therapy in the very elderly, the immuno-
suppressed, and those with prevalent cancer. Further-
more, long-term outcome data are needed in young in-
dividuals treated with statins for prolonged time peri-
ods. Perhaps a constant increase in Tregs over years,
even in the young, will weaken host antitumour immune
surveillance and increase the risk for various cancers.
In conclusion, we feel that there is ample evidence
that statins may promote cancer in certain segments
of the population. Currently, the indications for statin
therapy are based on lipoprotein levels, prevalent car-
diovascular disease, other vascular risk factors, and
family history 20. Maybe it is time for a new paradigm
that also includes age extremes, prevalent cancer, a
past history of cancer, and overall immunocompetence.
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